Are all programmed cell death protein 1 inhibitors the same?

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Programmed cell death protein 1 (PD-1) inhibitors are FDA-approved cancer therapies.
• No head-to-head Phase 3 randomized controlled trials (RCTs) exist to compare these agents.
• Understanding differences between PD-1 inhibitors is crucial for clinical decision-making.

Purpose of the Study:

• To review preclinical data comparing PD-1 inhibitors.
• To assess potential differentiating profiles of toripalimab versus pembrolizumab and nivolumab.
• To highlight the need for head-to-head trials to establish clinical differences.

Main Methods:

• Review of preclinical studies directly comparing PD-1 inhibitors.
• Analysis of binding characteristics (sites, orientations) and T cell function impact.
• Examination of clinical trial findings in nasopharyngeal carcinoma and non-small cell lung cancer.

Main Results:

• Preclinical data suggest toripalimab has a distinct profile from pembrolizumab and nivolumab regarding PD-1 interaction and T cell modulation.
• Toripalimab plus chemotherapy showed comparable or superior survival benefits in low/no PD-L1 expressing patients with advanced cancers.
• Observed benefits in overall survival and progression-free survival in specific cancer types.

Conclusions:

• Preclinical evidence suggests potential differences among PD-1 inhibitors.
• Toripalimab demonstrates promising efficacy, particularly in certain patient subgroups.
• Further head-to-head RCTs are essential to definitively establish clinically meaningful differences between PD-1 inhibitors.